Update in the approach to and management of heart failure

Southern Medical Journal

Volumn 99, Issue 12, 2006, Pages 1346-1355

  Gelow, Jill M ^a   Fang, James C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Aldosterone antagonists; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Beta blockers; Digoxin; Heart failure; Left ventricular dysfunction

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; BUCINDOLOL; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOLAZONE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; VALSARTAN;

AGE DISTRIBUTION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FOLLOW UP; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PERFORMANCE; HEMODYNAMIC MONITORING; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LONGEVITY; LOW DRUG DOSE; MORTALITY; PATIENT MONITORING; PROGNOSIS; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; SURVIVAL TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; DIGOXIN; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN;

EID: 33845939756     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000224752.85714.11     Document Type: Review

References (67)

1. Hunt SA., American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:1116-1143.
2. Fang JC, Givertz MM. Diastolic Heart Failure: Treatment of Advanced Heart Disease. Baughman KL, ed. New York, Taylor and Francis, 2006,pp 229-247.
3. Mahon N, Murphy RT, MacRae CA, et al. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005;143:108-115.
4. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction: SOLVD Investigators. JAMA 1993;270:1702-1707.
5. Stevenson LW, Couper G, Natteson B, et al. Target heart failure populations for newer therapies. Circulation 1995;92(9 Suppl):II-174-II-181.
6. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628-640.
7. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797-1804.
8. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971;285:1441-1446.
9. Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem 2005;40:1-36.
10. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-982.
11. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis for the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-570.
12. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006;47:85-90.
13. Rousseu MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40:1596-1601.
14. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational study. J Am Coll Cardiol 2003;41:2010-2017.
15. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-1259.
16. Nakamura M, Tanaka F, Sato K, et al. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. J Card Fail 2005;11:705-712.
17. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergent diagnosis of heart failure. N Engl J Med 2002;347:161-167.
18. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
19. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663.
20. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-2397.
21. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003;107:1278-1283.
22. HOPE Investigators. Effects of an angiotensin-converting-enzymes inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
23. Desai AS, Koplan B. The Role of ICDs in Advanced Heart Failure: Treatment of Advanced Heart Disease. Baughman KL, ed. New York, Taylor and Francis, 2006.
24. Rosenberg J, Gustafsson F, Galatius S, et al. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther 2005;19:301-306.
25. Gottleib SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000;35:56-59.
26. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
27. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
28. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551.
29. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the Consensus Trial Study Group. N Engl J Med 1987;316:1429-1435.
30. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
31. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: SOLVD Investigators. N Engl J Med 1991;325:293-302.
32. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejections fractions: SOLVD Investigators. N Engl J Med 1992;327:685-691.
33. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial: the SAVE Investigators. N Engl J Med 1992;327:669-667.
34. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61.
35. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS Study Group Circulation 1999;100:2312-2318.
36. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limitations to angiotensin-converting inhibitor identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003;41:2029-2035.
37. Brislow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-569.
38. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic HF in CIBIS II trial. Circulation 2001;103:1428-1433.
39. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockage in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-1191.
40. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treatment with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-1161.
41. Fang JC. Angiotensin-converting enzyme inhibitors or β-blockers in heart failure: does it matter who goes first? Circulation 2005;112:2380-2392.
42. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction: the Carvediolol and ACE-inhibitor Remodeling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovasc Drugs Ther 2004;18:57-66.
43. Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzymes inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004;44:1825-1830.
44. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effects on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III trial. Circulation 2005;112:2426-2435.
45. Packer M, Fowler MB, Coats AJ, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe heart failure. N Engl J Med 2001;344:1651-1658.
46. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure: MERIT-HF Study Group. Lancet 1999;353:2001-2007.
47. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
48. The Beta Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-1657.
49. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): a randomized control trial. Lancet 2003;362:7-13.
50. Jacob S, Rett K, Wicklmayr M, et al. Differential effects of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-494.
51. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction: results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) registry. Eur Heart J 1999;20:1182-1190.
52. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzymes inhibitors. Am Heart J 2000;139:609-617.
53. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
54. Pitt B, Pool-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
55. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
56. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic congestive heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;262:772-776.
57. McMurray JJ, Ostergren J, Sewdberg K, et al. Effects of candestartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003;362:767-771.
58. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction of both. N Engl J Med 2003;349:1893-1906.
59. Krum H, Bigger JT Jr, Goldsmith RL, et al. Effect of long-term digoxin therapy on autonomic function in patients with congestive heart failure. J Am Coll Cardiol 1995;25:289-94.
60. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzymes inhibitors: RADIANCE STUDY. N Engl J Med 1993;329:1-7.
61. The effect of digoxin on mortality and morbidity inpatients with heart failure: the Digitalis Investigation Group. N Engl J Med 1997;336:525-533.
62. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-1411.
63. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial: PROVED Investigators Group. J Am Coll Cardiol 1993;22:955-962.
64. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefit of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946-953.
65. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasdodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative study. N Engl J Med 1986;314:1547-1552.
66. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.
67. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-384.